Biologics Manufacturing Centre
Headquarters: Quebec
Summary
Reconnect with current stakeholders and build additional connections to help the market entry.
About
The Biologics Manufacturing Centre (BMC) is Canada’s flagship GMP licensed biomanufacturing facility, providing end to end services across the biologics value chain, from early clinical development through to commercial production. BMC offers a fully integrated “molecule to market” platform, including: • Process development and technology transfer • Drug substance manufacturing (e.g., vaccines, monoclonal antibodies, viral vectors, and biosimilars) • Analytical testing and quality control • Fill finish and aseptic manufacturing • Secondary packaging and release support Operating under a Health Canada Drug Establishment License and aligned with global regulatory standards, BMC enables both clinical and commercial scale production within a single, GMP compliant site. With a public good mandate and flexible operating model, BMC serves as a low-risk entry point for international partners, offering: • Rapid access to North American manufacturing capacity • Reduced capital investment through use of existing infrastructure • Support for co-development, scale up, and market entry strategies As a trusted partner, BMC is uniquely positioned to accelerate global collaborations and support Korean companies seeking to expand into North America through reliable, high-quality biomanufacturing solutions.